Oppenheimer set a $67.00 target price on Biohaven Pharmaceutical (NYSE:BHVN) in a research report sent to investors on Wednesday morning, TipRanks reports. The firm currently has a buy rating on the stock.
A number of other analysts have also weighed in on BHVN. Goldman Sachs Group set a $89.00 target price on shares of Biohaven Pharmaceutical and gave the stock a buy rating in a research note on Wednesday, September 4th. Cantor Fitzgerald set a $87.00 price target on Biohaven Pharmaceutical and gave the company a buy rating in a report on Wednesday, September 4th. ValuEngine downgraded Biohaven Pharmaceutical from a buy rating to a hold rating in a report on Wednesday, June 19th. Zacks Investment Research downgraded Biohaven Pharmaceutical from a buy rating to a hold rating in a report on Friday, July 19th. Finally, Morgan Stanley set a $50.00 price target on Biohaven Pharmaceutical and gave the company a hold rating in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Biohaven Pharmaceutical currently has a consensus rating of Buy and an average target price of $69.27.
BHVN stock opened at $43.01 on Wednesday. The company’s 50 day moving average price is $42.37 and its 200 day moving average price is $49.16. Biohaven Pharmaceutical has a fifty-two week low of $29.17 and a fifty-two week high of $67.86. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -6.99 and a beta of 0.32.
Biohaven Pharmaceutical (NYSE:BHVN) last released its earnings results on Thursday, August 8th. The company reported ($2.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.09) by ($0.26). As a group, sell-side analysts forecast that Biohaven Pharmaceutical will post -7.51 earnings per share for the current fiscal year.
In other news, Director Gregory Bailey acquired 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was acquired at an average cost of $37.65 per share, with a total value of $188,250.00. Following the completion of the acquisition, the director now owns 2,587,601 shares of the company’s stock, valued at $97,423,177.65. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Eric Aguiar sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $45.00, for a total value of $450,000.00. The disclosure for this sale can be found here. Corporate insiders own 23.90% of the company’s stock.
Several hedge funds have recently bought and sold shares of BHVN. Nuveen Asset Management LLC acquired a new stake in shares of Biohaven Pharmaceutical in the second quarter valued at approximately $38,799,000. Bank of New York Mellon Corp lifted its holdings in shares of Biohaven Pharmaceutical by 236.8% during the second quarter. Bank of New York Mellon Corp now owns 545,594 shares of the company’s stock worth $23,892,000 after purchasing an additional 383,594 shares during the period. Brown Advisory Inc. lifted its holdings in shares of Biohaven Pharmaceutical by 60.7% during the second quarter. Brown Advisory Inc. now owns 1,008,046 shares of the company’s stock worth $44,144,000 after purchasing an additional 380,764 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Biohaven Pharmaceutical by 34.2% during the second quarter. Vanguard Group Inc. now owns 1,154,257 shares of the company’s stock worth $50,545,000 after purchasing an additional 294,098 shares during the period. Finally, Luminus Management LLC acquired a new stake in shares of Biohaven Pharmaceutical during the second quarter worth $12,572,000. 90.90% of the stock is owned by institutional investors and hedge funds.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Featured Story: Earnings Per Share (EPS)
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.